This study was conducted to evaluate the safety and tolerance of desloratadine after 5 weeks of repetitive dosing in children ages 2 to 12 years old with allergic hypersensitivity or chronic hives. All of the subjects enrolled in this trial were previously identified in an earlier trial to be poor metabolizers of desloratadine.

Inclusion Criteria:

Subjects must:

• have been previously identified through the previous study P03031 to be atopic or with chronic idiopathic urticaria and be a poor metabolizer of desloratadine.
• have clinical laboratory tests within normal limits.
• be in good health, free of any clinically significant disease that could interfere with the study.
• normal 12-lead ECG

Exclusion Criteria:

Subjects who:

• have a history of any clinically significant local or systemic infectious disease within 4 weeks prior to treatment.
• have taken any medication that is restricted by the protocol or failed to satisfy washout requirements.
• are allergic to desloratadine.
• have used a loratadine- or desloratadine-containing product within the past 30 days.
• are female and menstruating.